ইউরোপীয় ইউনিয়ন - আইসল্যান্ডীয় - EMA (European Medicines Agency)

teva pharma b.v. - budesonide, formoterol fumarate dihydrate - pulmonary disease, chronic obstructive; asthma - lyf til veikindi öndunarvegi sjúkdómum, - asthma biresp spiromax is indicated in adults and adolescents (12 years and older) for the regular treatment of asthma, where use of a combination (inhaled corticosteroid and long-acting β₂ adrenoceptor agonist) is appropriate:in patients not adequately controlled with inhaled corticosteroids and “as needed” inhaled short-acting β₂ adrenoceptor agonists. orin patients already adequately controlled on both inhaled corticosteroids and long-acting β₂ adrenoceptor agonists. copdbiresp spiromax is indicated in adults, aged 18 years and older, for the symptomatic treatment of patients with copd with forced expiratory volume in 1 second (fev₁).

ইউরোপীয় ইউনিয়ন - আইসল্যান্ডীয় - EMA (European Medicines Agency)

teva pharma b.v. - budesonide, formoterol fumarate dihydrate - pulmonary disease, chronic obstructive; asthma - lyf til veikindi öndunarvegi sjúkdómum, - asthma duoresp spiromax is indicated in adults and adolescents (12 years and older) for the regular treatment of asthma, where use of a combination (inhaled corticosteroid and long-acting β₂ adrenoceptor agonist) is appropriate:in patients not adequately controlled with inhaled corticosteroids and “as needed” inhaled short-acting β₂ adrenoceptor agonists. orin patients already adequately controlled on both inhaled corticosteroids and long-acting β₂ adrenoceptor agonists. copdduoresp spiromax is indicated in adults, aged 18 years and older for the symptomatic treatment of patients with copd with forced expiratory volume in 1 second (fev₁).

ইউরোপীয় ইউনিয়ন - আইসল্যান্ডীয় - EMA (European Medicines Agency)

astrazeneca ab - glycopyrronium, formoterol fumarate dihydrate - lungnasjúkdómur, langvarandi hindrandi - formóteróli og þannig brómíð - bevespi aerosphere er ætlað sem viðhald berkjuvíkkandi meðferð til að létta einkenni í fullorðinn sjúklinga með langvinn veikindi í lungum (llt).

ইউরোপীয় ইউনিয়ন - আইসল্যান্ডীয় - EMA (European Medicines Agency)

teva pharma b.v.  - budesonide, formoterol fumarate dihydrate - asthma; pulmonary disease, chronic obstructive - lyf til veikindi öndunarvegi sjúkdómum, - budesonid / formoterol teva pharma b. er ætlað fullorðnum 18 ára og eldri. asthmabudesonide/formóteróli sjá pharma b. er gefið til kynna í reglulega meðferð asma, þar að nota sambland (andað barksteri og langverkandi β2 adrenviðtaka örva) er rétt:-í sjúklingar ekki nægilega stjórnað með andað krefur og "og þarf" andað skamms vinna β2 adrenviðtaka örvum. eða-í sjúklinga þegar nægilega stjórn á báðum andað krefur og langverkandi β2 adrenviðtaka örvum. copdsymptomatic meðferð sjúklinga með llt með afl útöndunarmagni í 1 annað (fev1) .

আইসলণ্ড - আইসল্যান্ডীয় - LYFJASTOFNUN (Icelandic Medicines Agency)

krka, d.d., novo mesto - tramadolum hýdróklóríð - forðatafla - 200 mg

আইসলণ্ড - আইসল্যান্ডীয় - LYFJASTOFNUN (Icelandic Medicines Agency)

stada arzneimittel ag - gabapentinum inn - hart hylki - 400 mg

আইসলণ্ড - আইসল্যান্ডীয় - LYFJASTOFNUN (Icelandic Medicines Agency)

stada arzneimittel ag - gabapentinum inn - hart hylki - 300 mg

আইসলণ্ড - আইসল্যান্ডীয় - LYFJASTOFNUN (Icelandic Medicines Agency)

krka, d.d., novo mesto - tramadolum hýdróklóríð - forðatafla - 100 mg

আইসলণ্ড - আইসল্যান্ডীয় - LYFJASTOFNUN (Icelandic Medicines Agency)

krka, d.d., novo mesto - tramadolum hýdróklóríð - forðatafla - 150 mg

ইউরোপীয় ইউনিয়ন - আইসল্যান্ডীয় - EMA (European Medicines Agency)

orion corporation - entacapone - parkinsonsveiki - anti-parkinsonslyf - skammti er ætlað sem viðbót til að standard undirbúning algengari / benserazide eða algengari / ddc hemli til að nota í fullorðinn sjúklinga með parkinsonsveiki og enda-af-skammt mótor sveiflur, sem ekki er hægt að stöðug á þeim sturtu.